Trial intelligence / Profile preview

Zanubrutinib for Active Proliferative Lupus Nephritis

CTR20202662Phase 2Completed

Sponsor
BeiGene
Start
Dec 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of zanubrutinib in lupus nephritis (LN), sponsored by BeiGene. Started Dec 2020; status: completed.

02

Drugs

zanubrutinib
03

Conditions

lupus nephritis (LN)

Beyond the preview

Go deeper on CTR20202662.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20202662.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call